Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Huaibin Ge"'
Autor:
Arpitha H. Shivarudrappa, Jessy John, Monika Vashisht, Huaibin Ge, Silvia Liu, Jingxin Chen, Karen Siddoway, Rui Dong, Zhangguo Chen, Jing H. Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Human papilloma virus (HPV) is an etiological factor of head and neck squamous cell carcinoma (HNSCC). To investigate the role of HPV antigen in anti-tumor immunity, we established mouse models by expressing HPV16 E6 and E7 in a SCC tumor cell line.
Externí odkaz:
https://doaj.org/article/a4f25552ea5c458f829ea2dd07b38b2a
Autor:
Chenxi Gao, Huaibin Ge, Shih-Fan Kuan, Chunhui Cai, Xinghua Lu, Farzad Esni, Robert E Schoen, Jing H Wang, Edward Chu, Jing Hu
Publikováno v:
eLife, Vol 13 (2024)
BRAFV600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAFV600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also t
Externí odkaz:
https://doaj.org/article/e2a122bab7f34dd78f4661a9fc648667
Autor:
Monika Vashisht, Huaibin Ge, Jessy John, Harlie A. McKelvey, Jingxin Chen, Zhangguo Chen, Jing H. Wang
Publikováno v:
Cell Death and Disease, Vol 14, Iss 9, Pp 1-15 (2023)
Abstract Deletion of TRAF2 or TRAF3 in B cells prolongs their survival. However, it remains unknown whether deletion of such factors affects B cells’ ability to tolerate DNA damage, which can be induced by chemotherapeutics and cause apoptosis. Gen
Externí odkaz:
https://doaj.org/article/3f89235a4a394b3495c5a44df88a97b4
Autor:
Jessy John, Samantha M. Y. Chen, Rachel A. Woolaver, Huaibin Ge, Monika Vashisht, Ziyu Huang, Zhangguo Chen, Jing H. Wang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, the responses to ICI treatment are highly variable in different individuals and the underlying mechanisms remain poorly understood. Here, we employed a mouse squamous
Externí odkaz:
https://doaj.org/article/d37efbe2fd27490894a7e6687b1d22c5
Autor:
Samantha M. Y. Chen, Vince Popolizio, Rachel A. Woolaver, Huaibin Ge, Alexandra L. Krinsky, Jessy John, Etienne Danis, Yao Ke, Yonatan Kramer, Li Bian, Andrew G. Nicklawsky, Dexiang Gao, Silvia Liu, Zhangguo Chen, Xiao-jing Wang, Jing H. Wang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-24 (2022)
Abstract Background While immune checkpoint inhibitors (ICI) were approved for head and neck squamous cell carcinomas (HNSCCs), the response rate remains relatively low. Mechanisms underlying ICI unresponsiveness versus sensitivity are not fully unde
Externí odkaz:
https://doaj.org/article/fe3ccf84926d43a5bceb19b100126efd
Autor:
Jessy John, Rachel A. Woolaver, Vince Popolizio, Samantha M. Y. Chen, Huaibin Ge, Alexandra L. Krinsky, Monika Vashisht, Yonatan Kramer, Zhangguo Chen, Jing H. Wang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Differential responses to immune checkpoint inhibitors (ICI) may be attributed to tumor-intrinsic factors or environmental cues; however, these mechanisms cannot fully explain the variable ICI responses in different individuals. Here, we investigate
Externí odkaz:
https://doaj.org/article/f5b78caa49bf4ebaae7aefd9334011c3
Publikováno v:
Beilstein Journal of Organic Chemistry, Vol 14, Iss 1, Pp 1452-1458 (2018)
The reaction of enamine compounds with the Togni reagent in the presence of CuI afforded β-trifluoromethylated enamine intermediates, which were converted directly to biologically interesting trifluoromethylated 2H-azirines by an iodosobenzene (PhIO
Externí odkaz:
https://doaj.org/article/5d55fe3741464b6bbf6642917723c5e5
Autor:
Shivarudrappa, Arpitha H., John, Jessy, Vashisht, Monika, Huaibin Ge, Silvia Liu, Jingxin Chen, Siddoway, Karen, Rui Dong, Zhangguo Chen, Wang, Jing H.
Publikováno v:
Frontiers in Immunology; 2024, p1-15, 15p
Autor:
Chenxi Gao, Huaibin Ge, Shih-Fan Kuan, Chunhui Cai, Xinghua Lu, Esni, Farzad, Schoen, Robert E., Wang, Jing H., Chu, Edward, Jing Hu
Publikováno v:
eLife; 6/26/2024, p1-21, 21p
Publikováno v:
Clinical Cancer Research. 29:647-658
Purpose: Cetuximab is a standard-of-care treatment for head and neck squamous cell carcinoma (HNSCC). Well-defined correlative markers of therapeutic responses are still lacking. Characterizing dynamic changes of T-cell receptor (TCR) repertoire in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ca2c7f52dd2d293a686240a2e5fce57
https://doi.org/10.1158/1078-0432.ccr-22-2355
https://doi.org/10.1158/1078-0432.ccr-22-2355